Skip to content
-
Subscribe to our newsletter & never miss our best posts. Subscribe Now!
Itfy.in

At Itfy, we are dedicated to revolutionizing the way you receive news. Our mission is to provide timely, accurate, and personalized news updates using cutting-edge AI technology. Stay informed, stay ahead with us.

Itfy.in

At Itfy, we are dedicated to revolutionizing the way you receive news. Our mission is to provide timely, accurate, and personalized news updates using cutting-edge AI technology. Stay informed, stay ahead with us.

  • Home
  • News Updates
    • Latest News
    • Entertainment News
    • Northeast News
  • Technology
    • Digital Transformation
    • Artificial Intelligence
    • Machine Learning
    • Generative AI
    • Cybersecurity
  • Education & Growth
    • Education
    • Lifelong Learning
    • Parenting
    • Career Growth
  • Startup & Entrepreneurship
    • Remote Work
    • Startups
    • Digital Marketing
    • Social Media
    • Entrepreneurship
    • Lean Thinking
    • Personal Finance
  • Climate Justice
    • Climate Tech
  • Health & Wellness
    • Mental Health
  • Tourism
  • Home
  • News Updates
    • Latest News
    • Entertainment News
    • Northeast News
  • Technology
    • Digital Transformation
    • Artificial Intelligence
    • Machine Learning
    • Generative AI
    • Cybersecurity
  • Education & Growth
    • Education
    • Lifelong Learning
    • Parenting
    • Career Growth
  • Startup & Entrepreneurship
    • Remote Work
    • Startups
    • Digital Marketing
    • Social Media
    • Entrepreneurship
    • Lean Thinking
    • Personal Finance
  • Climate Justice
    • Climate Tech
  • Health & Wellness
    • Mental Health
  • Tourism
Close

Search

  • https://www.facebook.com/
  • https://twitter.com/
  • https://t.me/
  • https://www.instagram.com/
  • https://youtube.com/
Subscribe
Home/News/Bharat Bio Triumphs in Phase III Trials of Revolutionary Oral Cholera Vaccine Hillchol | A Game Changer for India!
News

Bharat Bio Triumphs in Phase III Trials of Revolutionary Oral Cholera Vaccine Hillchol | A Game Changer for India!

By adminitfy
May 21, 2025 2 Min Read

Bharat Biotech, based in Hyderabad, announced a significant breakthrough on Wednesday with its oral cholera vaccine, Hillchol, successfully completing Phase III clinical trials. This vaccine has demonstrated efficacy against both the Ogawa and Inaba serotypes of the cholera bacteria, showing an impressive increase in vibriocidal antibodies-68.3% for Ogawa and 69.5% for Inaba. The results indicate that Hillchol is non-inferior to existing licensed vaccines, maintaining a strong safety profile across all ages with only mild adverse events reported.

The findings, published in the ScienceDirect vaccine journal, stem from a comprehensive double-blind, randomized trial that involved 1,800 participants, ranging from infants to adults, across ten clinical sites in India. Participants were divided into three age groups-adults over 18, children aged 5 to under 18, and infants aged 1 to under 5. They were randomly assigned in a 3:1 ratio to receive either Hillchol or a comparator vaccine, Shanchol.

Dr. Krishna Ella, executive chairman of Bharat Biotech, highlighted the potential impact of Hillchol in addressing the global cholera crisis and vaccine shortages. He emphasized that this new-generation oral cholera vaccine utilizes a simplified single stable O1 Hikojima strain, enhancing production efficiency and affordability, which is vital for lower- and middle-income countries. Bharat Biotech’s facilities in Hyderabad and Bhubaneswar are capable of producing 200 million doses of Hillchol annually, which could help alleviate the current global demand for cholera vaccines, estimated at 100 million doses per year versus a singular manufacturer supply.

Cholera remains a significant public health threat, causing over 2.86 million cases and approximately 95,000 deaths worldwide each year due to ingested food or water contaminated with the Vibrio cholerae bacteria. Given that Bharat Biotech has a strong portfolio-having delivered over nine billion doses globally, holding more than 145 global patents, and with registrations in over 125 countries-the development of Hillchol adds to its notable vaccine offerings.

In addition to Hillchol, Bharat Biotech has previously developed Covaxin, India’s first indigenous COVID-19 vaccine, alongside vaccines targeting diseases like influenza H1N1, rotavirus, Japanese Encephalitis (Jenvac), rabies, chikungunya, Zika, and pioneering a tetanus-toxoid conjugated vaccine for typhoid.

As vaccination campaigns continue to be crucial in combatting infectious diseases, the release of Hillchol marks a promising advancement in public health efforts, particularly for vulnerable populations in regions frequently impacted by cholera outbreaks. Bharat Biotech’s commitment to innovation and accessibility positions it as a leader in the global vaccination landscape, poised to make a substantial difference in the fight against cholera and other infectious diseases.

This development not only reflects Bharat Biotech’s dedication to addressing pressing health challenges but also underscores the importance of advancing vaccine production capabilities to meet growing global needs.

Original Source: https://timesofindia.indiatimes.com/india/bharat-bio-successfully-completes-phase-iii-trials-of-new-oral-cholera-vaccine-hillchol/articleshow/121322323.cms
Category :
Tags:
Publish Date: 2025-05-21 23:03:00

Author

adminitfy

Follow Me
Other Articles
Previous

Kerala Lottery Results for May 21, 2025: Discover Today’s Winning Numbers!

Next

Can Technology Be the Bridge? Reimagining Assam’s Growth Through Human-Centered Innovation

No Comment! Be the first one.

Leave a Reply Cancel reply

You must be logged in to post a comment.

Search...

Recent Posts

  • Nepal PM Balendra Shah to Meet India's Modi on First Foreign Trip
    Nepal PM Balendra Shah to Meet India’s Modi on First Foreign Trip
    by adminitfy
    November 21, 2026
  • Empowering Northeast India: CII’s CSR Connect Event Ignites Social Development
    by adminitfy
    July 3, 2024
  • Urgent Crisis: Northeast on High Alert as Death Toll Tragically Rises in Assam
    by adminitfy
    July 3, 2024
  • Triumphant Breakthrough: Security Forces Successfully Capture 4 Insurgents in Manipur Operation
    by adminitfy
    July 3, 2024

Welcome to the ultimate source for fresh perspectives! Explore curated content to enlighten, entertain and engage global readers.

  • Facebook
  • X
  • Instagram
  • LinkedIn

Latest Posts

  • Nepal PM Balendra Shah to Meet India’s Modi on First Foreign Trip
  • Buzz: I Play Rocky Star P.J. Byrne’s Journey to Hollywood Go-To Character Actor Unveiled-Exclusive Must-Watch!
  • Manipur BJP MLA Dies in Delhi Hospital; Leaders Mourn Tragic Loss
  • NYC Mayor Zohran Mamdani Injured in Soccer Match vs Journalists
  • The Post-SWIFT Payments Stack: Architecting Stablecoin Settlement
  • November 2026 (647)
  • October 2026 (646)
  • September 2026 (524)
  • August 2026 (1001)
  • July 2026 (986)
  • June 2026 (963)
  • May 2026 (922)
  • April 2026 (1525)
  • March 2026 (1522)
  • February 2026 (1252)
  • January 2026 (968)
  • December 2025 (942)
  • November 2025 (853)
  • October 2025 (869)
  • September 2025 (733)
  • August 2025 (810)
  • July 2025 (720)
  • June 2025 (1244)
  • May 2025 (2201)
  • April 2025 (1481)
  • March 2025 (2020)
  • February 2025 (1159)
  • January 2025 (1440)
  • December 2024 (1499)
  • November 2024 (1771)
  • October 2024 (1815)
  • September 2024 (1750)
  • August 2024 (1458)
  • July 2024 (1268)

Contact

Email

info@itfy.in

Location

INDIA

Copyright 2026 — Itfy.in. All rights reserved.